. "C\u00EDl. Posoudit mo\u017Enosti vyu\u017Eit\u00ED 18F-FDOPA-PET/CT v zobrazen\u00ED neuroendokrinn\u00EDch n\u00E1dor\u016F karcinoidov\u00E9ho typu. Metoda. Byl hodnocen soubor 16 zobrazen\u00ED 18F-FDOPA-PET/CT u 13 nemocn\u00FDch s NET, kter\u00E1 byla provedena pro staging nebo restaging NET. Vy\u0161et\u0159en\u00ED byla provedena po aplikaci 18F-FDOPA v d\u00E1vce 1-2 MBq/kg, sou\u010D\u00E1st\u00ED vy\u0161et\u0159en\u00ED bylo pln\u011B diagnostick\u00E9 dvouf\u00E1zov\u00E9 MDCT. Byla hodnocena pr\u016Fm\u011Brn\u00E1 akumulace radiofarmaka v prim\u00E1rn\u00EDm n\u00E1doru, jatern\u00EDch, kostn\u00EDch a uzlinov\u00FDch metast\u00E1z\u00E1ch a vztah maxim\u00E1ln\u00ED n\u00E1dorov\u00E9 akumulace k aplikovan\u00E9 aktivit\u011B. V\u00FDsledky. Celkem jsme provedli vy\u0161et\u0159en\u00ED u dev\u00EDti karcinoid\u016F st\u0159eva, t\u0159\u00ED urogenit\u00E1ln\u00EDch karcinoid\u016F, u jednoho plicn\u00EDho karcinoid\u016F a jednoho pankreatick\u00E9ho polypeptidomu. Pr\u016Fm\u011Brn\u00E1 \u00FArove\u0148 akumulace 18F-FDOPA u karcinoid\u016F dos\u00E1hla v jatern\u00EDch metast\u00E1z\u00E1ch SUVmax 13,75, v uzlinov\u00FDch metast\u00E1z\u00E1ch SUVmax 23,38, a v\u00FDrazn\u011B se li\u0161ila od akumulace pozad\u00ED. Nebyla prok\u00E1z\u00E1na z\u00E1vislost mezi aplikovanou aktivitou a maxim\u00E1ln\u00ED akumulac\u00ED v n\u00E1dorov\u00E9 tk\u00E1ni (p = 0,9195, korela\u010Dn\u00ED koeficient r = -0,03685). Nov\u00E9 informace byly zji\u0161t\u011Bny celkem u jeden\u00E1cti nemocn\u00FDch (84 %). Z\u00E1v\u011Br. 18F-FDOPA-PET/CT lze s v\u00FDhodou pou\u017E\u00EDt k hodnocen\u00ED rozsahu posti\u017Een\u00ED NET jak p\u0159i prim\u00E1rn\u00EDm stagingu, p\u0159i vyhled\u00E1v\u00E1n\u00ED prim\u00E1rn\u00EDho n\u00E1doru, ale i k posuzov\u00E1n\u00ED residu\u00E1ln\u00ED aktivity onemocn\u011Bn\u00ED."@cs . . "CZ - \u010Cesk\u00E1 republika" . . "F\u00EDnek, Jind\u0159ich" . . . "\u010Cesk\u00E1 radiologie" . "ZOBRAZEN\u00CD KARCINOIDN\u00CDCH N\u00C1DOR\u016E POMOC\u00CD PET/CT S POD\u00C1N\u00CDM 18F-FLUORODIHYDROXYFENYLALANINU" . "[8F64AC900EFB]" . . "67" . "IMAGING OF THE CARCINOIDTUMORS USING PET/CT WITH APPLICATION OF 18F-FLUORODIHYDROXYPHENYLALANINE"@en . "carcinoid; neuroendocrine tumors; PET/CT; 18F-FDOPA; 18F-fluorodihydroxyphenylalanine"@en . "RIV/00669806:_____/13:10138920" . . "RIV/00669806:_____/13:10138920!RIV14-MZ0-00669806" . . "I" . . . . . "ZOBRAZEN\u00CD KARCINOIDN\u00CDCH N\u00C1DOR\u016E POMOC\u00CD PET/CT S POD\u00C1N\u00CDM 18F-FLUORODIHYDROXYFENYLALANINU"@cs . . . "1" . "Kreuzberg, Boris" . "ZOBRAZEN\u00CD KARCINOIDN\u00CDCH N\u00C1DOR\u016E POMOC\u00CD PET/CT S POD\u00C1N\u00CDM 18F-FLUORODIHYDROXYFENYLALANINU" . "Skalick\u00FD, Tom\u00E1\u0161" . "Aim. To evaluate the a role of 18F-FDOPA-PET/CT in the imaging of neuroendocrine tumors (NET) of carcinoid type. Method. The sample of 16 18F-FDOPA-PET/CT examinations was assessed in patients suffered from NET of carcinoid type. All examinations were performed after intravenous administration of 18F-fiuorodihydroxyfenylalanine in the dose of 1-2 MBq per kilogram of body weight, when the full diagnostic dual-phase MDCT forms the integral part of the examination. The accumulation of the radiopharmaceutical was evaluated in primary tumor, liver metastases, bony metastases or infiltrated lymph nodes. Results. Nine bowel carcinoids, three urogenital carcinoids, one lung carcinoid, one pancreatic polypeptidoma were investigated. Mean SUV max reached 13.75 in liver metastases, in lymph nodes 23.38, and significantly differed from those measured in the background. The relation between applied radiopharmaceutical activity and maximum tumorous accumulation levels was not confirmed (p = 0.9195, correlation coefficient r = -0.03685). Conclusion. 18F-FDOPA-PET/CT is useful tool in the evaluation of the spread of NET even if the primary tumor is not previously detected. In such cases, the primary tumor could be detected effectively. Also the assessment of the disease activity is possible."@en . "IMAGING OF THE CARCINOIDTUMORS USING PET/CT WITH APPLICATION OF 18F-FLUORODIHYDROXYPHENYLALANINE"@en . . . . . "119153" . "T\u0159e\u0161ka, Vladislav" . "1210-7883" . "7"^^ . "Baxa, Jan" . . . "Holubec, Lubo\u0161" . "8"^^ . . . . "Ferdov\u00E1, Eva" . "C\u00EDl. Posoudit mo\u017Enosti vyu\u017Eit\u00ED 18F-FDOPA-PET/CT v zobrazen\u00ED neuroendokrinn\u00EDch n\u00E1dor\u016F karcinoidov\u00E9ho typu. Metoda. Byl hodnocen soubor 16 zobrazen\u00ED 18F-FDOPA-PET/CT u 13 nemocn\u00FDch s NET, kter\u00E1 byla provedena pro staging nebo restaging NET. Vy\u0161et\u0159en\u00ED byla provedena po aplikaci 18F-FDOPA v d\u00E1vce 1-2 MBq/kg, sou\u010D\u00E1st\u00ED vy\u0161et\u0159en\u00ED bylo pln\u011B diagnostick\u00E9 dvouf\u00E1zov\u00E9 MDCT. Byla hodnocena pr\u016Fm\u011Brn\u00E1 akumulace radiofarmaka v prim\u00E1rn\u00EDm n\u00E1doru, jatern\u00EDch, kostn\u00EDch a uzlinov\u00FDch metast\u00E1z\u00E1ch a vztah maxim\u00E1ln\u00ED n\u00E1dorov\u00E9 akumulace k aplikovan\u00E9 aktivit\u011B. V\u00FDsledky. Celkem jsme provedli vy\u0161et\u0159en\u00ED u dev\u00EDti karcinoid\u016F st\u0159eva, t\u0159\u00ED urogenit\u00E1ln\u00EDch karcinoid\u016F, u jednoho plicn\u00EDho karcinoid\u016F a jednoho pankreatick\u00E9ho polypeptidomu. Pr\u016Fm\u011Brn\u00E1 \u00FArove\u0148 akumulace 18F-FDOPA u karcinoid\u016F dos\u00E1hla v jatern\u00EDch metast\u00E1z\u00E1ch SUVmax 13,75, v uzlinov\u00FDch metast\u00E1z\u00E1ch SUVmax 23,38, a v\u00FDrazn\u011B se li\u0161ila od akumulace pozad\u00ED. Nebyla prok\u00E1z\u00E1na z\u00E1vislost mezi aplikovanou aktivitou a maxim\u00E1ln\u00ED akumulac\u00ED v n\u00E1dorov\u00E9 tk\u00E1ni (p = 0,9195, korela\u010Dn\u00ED koeficient r = -0,03685). Nov\u00E9 informace byly zji\u0161t\u011Bny celkem u jeden\u00E1cti nemocn\u00FDch (84 %). Z\u00E1v\u011Br. 18F-FDOPA-PET/CT lze s v\u00FDhodou pou\u017E\u00EDt k hodnocen\u00ED rozsahu posti\u017Een\u00ED NET jak p\u0159i prim\u00E1rn\u00EDm stagingu, p\u0159i vyhled\u00E1v\u00E1n\u00ED prim\u00E1rn\u00EDho n\u00E1doru, ale i k posuzov\u00E1n\u00ED residu\u00E1ln\u00ED aktivity onemocn\u011Bn\u00ED." . "ZOBRAZEN\u00CD KARCINOIDN\u00CDCH N\u00C1DOR\u016E POMOC\u00CD PET/CT S POD\u00C1N\u00CDM 18F-FLUORODIHYDROXYFENYLALANINU"@cs . . "Ferda, Ji\u0159\u00ED" . "8"^^ .